Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any inaccuracies are welcome. This article is only an introduction to medical and health-related drugs and does not recommend any treatment plans (if involved). This article does not constitute any investment advice.
Recently, AbbVie announced an investment of approximately 150 million euros (161 million US dollars) in Rhineland-Palatinate, Germany.New Central Research Building "LUnA" (LUdwighafen's New Working World), and is expected to be completed in 2027.The R&D base already has more than 2,000 employees, and the new building will accommodate over 300 employees in oncology, neuroscience, and immunology, which means 300 new jobs will be created. Since 2020, AbbVie has invested approximately 250 million euros (equivalent to 269 million U.S. dollars) in Germany.Martin Gastens, Vice President of Biologics Drug Product Development at AbbVie Germany and Managing Director of R&D, stated，For AbbVie, the new construction of our LUnA research building goes far beyond a 150 million euro investment in cutting-edge infrastructure. We are creating attractive working conditions for our top scientists and attracting new talent, so that we can conduct frontier research at our facility over the long term.In January this year, AbbVie's $223 million expansion project for its Singapore production facility broke ground, which will add over 100 jobs and additional biologics manufacturing capacity, with operations expected to begin in 2026. In 2022, the company also opened a new research institute in San Francisco.AbbVie has also invested in its product pipeline and portfolio, including the $10.1 billion acquisition of ADC biotech company ImmunoGen and the $8.7 billion acquisition of CNS company Cerevel.
